A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma
A phase 3 trial of Bempegaldesleukin and Nivolumab in Melanoma, run by Bristol-Myers Squibb, completed.
Overview
A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma is a phase 3 interventional study registered as NCT03635983 by Bristol-Myers Squibb, with 783 participants recorded, started 2018-09-21 and reaching its primary completion in 2021-11-19. Interventions recorded: NKTR-214, Nivolumab. Conditions recorded: Melanoma.
Linked to the drug Bempegaldesleukin because the registry names it among its interventions and Melanoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialStudy to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence
Shares Bempegaldesleukin, Nivolumab, Melanoma and the tag pipeline.
- TrialA Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
Shares Bristol Myers Squibb, Nivolumab and the tag pipeline.
- TrialA Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Shares Bristol Myers Squibb, Nivolumab and the tag pipeline.
- TrialA Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
Shares Bempegaldesleukin, Nivolumab and the tag pipeline.
- TrialA Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Shares Bristol Myers Squibb, Nivolumab and the tag pipeline.
- TrialA Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Shares Bristol Myers Squibb, Nivolumab and the tag pipeline.
- TrialStudy of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
Shares Bristol Myers Squibb, Nivolumab and the tag pipeline.
- TrialA Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)
Shares Bristol Myers Squibb and the tag pipeline.